<PAGE>
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __)
Filed by the Registrant /X/
Filed by a Party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/X/ Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
INTEGRA LIFESCIENCES CORPORATION
------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/X/ No fee required
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE>
[LOGO] INTEGRA LIFESCIENCES CORPORATION
- --------------------------------------------------------------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
- --------------------------------------------------------------------------------
<TABLE>
<S> <C>
TIME 9:15 a.m. on Monday, May 19, 1997
PLACE Princeton Marriott Forrestal Village
201 Village Boulevard
Princeton, New Jersey 08540
ITEMS OF BUSINESS 1. To elect seven directors to hold office as specified in the proxy
statement.
2. To appoint Coopers & Lybrand L.L.P. as auditors for the Company for the
current fiscal year.
3. To act upon any other matters properly coming before the meeting or any
adjournment or postponement thereof.
RECORD DATE Holders of Common Stock of record at the close of business on March 31, 1997
are entitled to vote at the meeting and any adjournment or postponement
thereof.
ANNUAL REPORT The 1996 Annual Report of Integra LifeSciences Corporation is being mailed
simultaneously herewith. The Annual Report is not to be considered part of the
proxy solicitation materials.
IMPORTANT In order to avoid additional soliciting expense to the Company, please MARK,
SIGN, DATE and MAIL your proxy PROMPTLY in the return envelope provided, even
if you plan to attend the meeting. If you attend the meeting and wish to vote
your shares in person, arrangements will be made for you to do so.
</TABLE>
<TABLE>
<S> <C>
By order of the Board of Directors,
/s/ William M. Goldstein
Plainsboro, New Jersey William M. Goldstein
April 16, 1997 Secretary
</TABLE>
<PAGE>
[LOGO] INTEGRA LIFESCIENCES CORPORATION
105 MORGAN LANE
PLAINSBORO, NEW JERSEY 08536
---------------------------------
PROXY STATEMENT
---------------------------------
This Proxy Statement, which is being sent to stockholders on or about April
17, 1997, is furnished in connection with the solicitation of proxies by the
Board of Directors of Integra LifeSciences Corporation (the 'Company') for use
at the forthcoming 1997 Annual Meeting of Stockholders to be held on Monday, May
19, 1997, at 9:15 a.m. local time at the Princeton Marriott Forrestal Village,
201 Village Boulevard, Princeton, New Jersey and at any adjournment or
postponement thereof.
Only stockholders of record as of the close of business on March 31, 1997
(the 'Record Date') will be entitled to notice of and to vote at the meeting or
at any adjournment or postponement thereof. On the Record Date, there were
outstanding 29,630,496 shares of Common Stock, which constituted the only
outstanding securities of the Company entitled to vote.
VOTING AND REVOCABILITY OF PROXIES
Each share of Common Stock has one vote. Directors are to be elected by a
plurality of the votes of the shares present, in person or by proxy, at the
meeting and entitled to vote. Cumulative voting in the election of directors is
not permitted. Ratification of the appointment of Coopers & Lybrand L.L.P. to
serve as the Company's independent accountants for 1997 requires the affirmative
vote of the holders of a majority of the shares of the Common Stock present, in
person or by proxy, at the meeting and entitled to vote. If a proxy is marked as
'Withhold Authority' or 'Abstain' on any matter, or if specific instructions are
given that no vote be cast on any specific matter (a 'Specified Non-Vote'), the
shares represented by such proxy will not be voted on such matter. Abstentions
will be included within the number of shares present at the meeting and entitled
to vote for the purposes of determining whether such matter has been authorized,
but nominee and other Specified Non-Votes will not be so included.
Shares may be voted at the meeting in person or by proxy. All valid proxies
received prior to the meeting will be voted. Unless marked to the contrary, such
proxies will be voted 'FOR' the election of all directors and 'FOR' the
appointment of Coopers & Lybrand L.L.P. as the Company's independent accountants
for 1997. If any other business is brought before the meeting, the proxies will
be voted, to the extent permitted by the rules of the Securities and Exchange
Commission, in accordance with the judgment of the persons voting the proxies. A
stockholder who has given a proxy may revoke it at any time prior to such proxy
being voted at the meeting by filing with the Secretary of the Company an
instrument revoking it or a duly executed proxy bearing a later date, or by
attending the meeting and giving notice of such revocation. Attendance at the
meeting does not by itself constitute revocation of a proxy.
In addition to the use of the mails, proxies may be solicited by the
directors, officers and employees of the Company, without additional
compensation, by personal interview, telephone, telegram, or otherwise.
Arrangements also may be made with brokerage firms and other custodians,
nominees and fiduciaries who hold the voting securities of record for the
forwarding of solicitation material to the beneficial owners thereof. The
Company will reimburse such brokers, custodians, nominees and fiduciaries for
the reasonable out-of-pocket expenses incurred by them in connection therewith.
<PAGE>
PROPOSAL 1. ELECTION OF DIRECTORS
The Board of Directors has nominated seven persons for election as
directors whose terms will expire at the 1998 Annual Meeting of Stockholders, or
when their successors are elected and qualified. The nominees are Keith Bradley,
Ph.D., Richard E. Caruso, Ph.D., William M. Goldstein, Esq., Frederic V. Malek,
George W. McKinney, III, Ph.D., James M. Sullivan and Edmund L. Zalinski, Ph.D,
all of whom are currently directors of the Company.
If any nominee should be unable to serve as director, an event not now
anticipated, it is intended that the shares represented by proxies will be voted
for the election of such substitute as the Board of Directors may nominate. Set
forth below is certain information with respect to the persons nominated as
directors of the Company.
KEITH BRADLEY, PH.D. has been a director of the Company since 1992. He is
the Professor of International Management and Director of Business Research at
The Open University Business School, Milton Keynes, England, and a Director of
Ockham Holdings plc, a London Stock Exchange corporation. Dr. Bradley was the
founder and formerly Executive Director of the London Business School of
Economics Performance Group, an interdisciplinary research institute which
specializes in organizational performance. He has extensive experience as a
consultant to a variety of business, government and international organizations
and has published widely on management and industrial policy. Since 1978, Dr.
Bradley has served as Visiting Professor at Harvard Business School, the UCLA
Graduate School of Management and the Wharton School of the University of
Pennsylvania. Dr. Bradley received a Diploma in Education from Culham College
and a Ph.D. degree in Economics from the University of Essex. Dr. Bradley is 52
years old.
RICHARD E. CARUSO, PH.D. has served as the Company's Chairman and Chief
Executive Officer since March 1992 and as the Company's President since
September 1995. From 1969 to 1992, Dr. Caruso was a principal of LFC Financial
Corporation, a project finance company, where he was also a director and
Executive Vice President. He has 25 years experience in finance and
entrepreneurial-type ventures. Dr. Caruso is on the Board of Susquehanna
University, The Baum School of Art and The Uncommon Individual Foundation
(Founder). He received a B.S. degree from Susquehanna University, an M.S.B.A.
degree from Bucknell University and a Ph.D. degree from the London School of
Economics, University of London (United Kingdom). Dr. Caruso is also a certified
public accountant. Dr. Caruso is 54 years old.
WILLIAM M. GOLDSTEIN, ESQ. has been a director of the Company since 1992.
He is a Managing Partner and Chairman of the Tax Group of the law firm of
Drinker Biddle & Reath L.L.P. Mr. Goldstein specializes in federal taxation,
securities law and general corporate law. From 1978 to 1982, he was Vice
Chairman of the Tax Section and Chairman of the Finance Committee of the law
firm of Morgan, Lewis & Bockius. He previously held the position of Deputy
Assistant Secretary for Tax Policy with the United States Department of
Treasury. Mr. Goldstein is active in many legal professional organizations and
has published extensively on topics related to taxation. He currently serves as
a Director of National Media Corporation and of Primary Health Systems, Inc. Mr.
Goldstein received an A.B. degree in Public and International Affairs from
Princeton University and a J.D. degree from Harvard Law School. Mr. Goldstein is
61 years old.
FREDERIC V. MALEK has been a director of the Company since 1992. He was
appointed by President Bush as Campaign Manager of Bush-Quayle '92 in December
1991. Previously, Mr. Malek was Vice Chairman of NWA, Inc. and its principal
operating unit, Northwest Airlines. He served as President of both companies
from 1989 to 1990. Mr. Malek also served as co-chairman of CB Commercial Real
Estate Group, a large real estate services company, from 1989 through October
1996 and serves as Chairman of Thayer Capital Partners. From 1981 through 1989,
he was President of Marriott Hotels. In addition to his business career, Mr.
Malek has served as an advisor to four United States Presidents, including
serving as Deputy Undersecretary of the Department of Health, Education and
Welfare, Deputy Director of the Office of Management and Budget and a member of
the President's Domestic Council under Presidents Nixon and Ford. Mr. Malek
advised President Reagan in several capacities, including as a member of the
Executive Committee of the President's Council on Cost Control and as a member
of the President's Commission on Private Sector Initiatives. He served President
Bush as Director of the 1988 Republican Convention and as Director of the 1990
Economic Summit of Industrialized Nations with the rank of Ambassador. He serves
on the board of directors of Automatic Data Processing Corp., American
Management Systems, Inc., Choice Hotels, Inc., Manor Care, Inc., National
Education Corp., Northwest Airlines, CB Commercial Real Estate Group, various
PaineWebber Mutual Funds and FPL Group, Inc., as well as on the boards of
several universities and non-profit
2
<PAGE>
institutions. Mr. Malek received a B.S. degree from the United States Military
Academy at West Point and an M.B.A. degree from Harvard Business School. Mr.
Malek is 60 years old.
GEORGE W. MCKINNEY, III, PH.D. has been a director of the Company since
1992 and has more than 25 years of experience in industry and new ventures.
Since 1990, Dr. McKinney has been Managing Director and co-founder of Beacon
Venture Management Corporation, a venture capital firm based in Waltham,
Massachusetts. Prior to his association with Beacon, he was Managing Partner and
Chief Operating Officer for American Research and Development, a Boston-based
venture capital firm. Dr. McKinney is currently President and Chief Executive
Officer for Gel Sciences, Inc. and its affiliate, GelMed, Inc., companies
involved in development of polymer gel technology. He previously held various
senior management positions with Corning, Inc. He is a director of American
Superconductor Corporation, Gel Sciences, Inc., GelMed, Inc., and Sensiv, Inc.
Dr. McKinney received a B.S. degree from MIT and a Ph.D. degree from the
Stanford University School of Business. Dr. McKinney is 53 years old.
JAMES M. SULLIVAN has been a director of the Company since 1992. Since
1986, he has held several positions with Marriott International, Inc. (and its
predecessor, Marriott Corp.), including Vice President of Mergers and
Acquisitions, and his current position of Executive Vice President of
Development for the Lodging Group of Marriott. From 1983 to 1986, Mr. Sullivan
was Chairman, President and Chief Executive Officer of Tenley Enterprises, Inc.,
a privately held company operating 105 restaurants. Prior to 1983, he held
senior management positions with Marriott Corp., Harrah's Entertainment, Inc.,
Holiday Inns, Inc., Kentucky Fried Chicken Corp. and Heublein, Inc. He also was
employed as a senior auditor with Arthur Andersen & Co. He received a B.S.
degree in Accounting from Boston College and an M.B.A. degree from the
University of Connecticut. Mr. Sullivan is also a certified public accountant.
Mr. Sullivan is 53 years old.
EDMUND L. ZALINSKI, PH.D. has been a director of the Company since 1992.
Since 1938, Dr. Zalinski has been active in a variety of public and privately
held companies engaged in insurance, mutual funds, banking, leasing and real
estate. From 1973 until he retired in 1992, he was Chairman of the Board of the
American Capital Open End Funds, a mutual fund management company. He was a
principal organizer and President of the Life Insurance Company of North America
and was Chairman and Chief Executive Officer of the Greenfield Real Estate
Investment Trust. He currently serves as Chairman of A+ Marketing Services. Dr.
Zalinski received a B.A. degree from Cornell University, an M.B.A. degree from
Harvard Business School and a Ph.D. degree from New York University. Dr.
Zalinski is 81 years old.
INFORMATION CONCERNING MEETINGS AND CERTAIN COMMITTEES
The Board of Directors held three formal meetings during 1996. The Company
has a standing Audit Committee, Compensation Committee and Stock Options
Committee of its Board of Directors.
The Audit Committee consists of Messrs. Goldstein and Sullivan. The Audit
Committee makes recommendations to the Board of Directors regarding the
selection of independent accountants, reviews the results and scope of the audit
and other services provided by the Company's independent accountants, and
reviews and evaluates the Company's internal accounting control. During 1996,
the Audit Committee met once.
The Compensation Committee consists of Messrs. Bradley and Caruso. The
Compensation Committee makes decisions concerning salaries and incentive
compensation for employees and consultants of the Company. During 1996, the
Compensation Committee met once.
The Stock Options Committee consists of Messrs. Bradley and Zalinski. The
Stock Options Committee makes decisions concerning issuance of stock options to
employees and consultants of the Company and also administers the Company's 1992
Stock Option Plan and the Company's 1993 Incentive Stock Option and
Non-Qualified Stock Option Plan. During 1996, the Stock Options Committee met
once.
During 1996, all incumbent directors attended in person or by conference
telephone at least 75% of the total number meetings of the Board of Directors
and committees of the Board on which they served during their incumbency.
3
<PAGE>
COMPENSATION OF DIRECTORS
The Company has not paid any cash compensation to its directors for their
service as directors. The Company pays reasonable travel and out-of-pocket
expenses incurred by non-employee directors in connection with attendance at
meetings to transact the business of the Company or attendance at meetings of
the Board of Directors or any committee thereof. In 1992 Messrs. Bradley,
Goldstein, Malek, McKinney, Sullivan and Zalinski were each granted an option to
acquire 42,500 shares of Common Stock at an exercise price of $.265 per share
which become exercisable with respect to 1.6667% of such shares on the first day
of each month following the award date.
PROPOSAL 2. RATIFICATION OF APPOINTMENT OF AUDITORS
The firm of Coopers & Lybrand L.L.P. served as the Company's independent
accountants for 1996 and has been selected by the Board of Directors to serve in
the same capacity for 1997. The stockholders will be asked to ratify this
appointment at the meeting. The ratification of independent accountants by the
stockholders is not required by law or the Company's By-laws. Traditionally, the
Company has submitted this matter to the stockholders and believes that it is
good practice to continue to do so. The affirmative vote of holders of a
majority of the outstanding shares of Common Stock present, in person or by
proxy, at the meeting and entitled to vote is required to ratify the appointment
of Coopers & Lybrand L.L.P. If a majority of the votes cast on this matter are
not cast in favor of the ratification of Coopers & Lybrand L.L.P., the Company
will appoint other independent accountants as soon as practicable and before the
close of the 1997 year.
A representative of Coopers & Lybrand L.L.P. is expected to be present at
the meeting and will be available to respond to appropriate questions. The
representative will also have the opportunity to make a statement if he or she
desires to do so.
THE BOARD OF DIRECTORS RECOMMENDS VOTING 'FOR' RATIFICATION OF THE
APPOINTMENT OF COOPERS & LYBRAND L.L.P. AS THE COMPANY'S INDEPENDENT ACCOUNTANTS
FOR 1997.
ADDITIONAL INFORMATION
OTHER MATTERS
The Board of Directors knows of no matters to be presented for action at
the meeting other than those set forth in the attached notice and customary
procedural matters. However, if any other matters should properly come before
the meeting or any adjournments or postponements thereof, the proxies solicited
hereby will be voted on such matters, to the extent permitted by the rules of
the Securities and Exchange Commission, in accordance with the judgment of the
persons voting such proxies.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended (the
'Exchange Act'), requires the Company's directors and executive officers, as
well as persons beneficially owning more than 10% of the Company's outstanding
shares of Common Stock and certain other holders of such shares (collectively,
'Covered Persons'), to file with the Securities and Exchange Commission and the
Nasdaq Stock Market, within specified time periods, initial reports of
ownership, and subsequent reports of changes in ownership, of Common Stock and
other equity securities of the Company.
Based solely upon the Company's review of copies of such reports furnished
to it and upon representations of Covered Persons that no other reports were
required, to the Company's knowledge all of the Section 16(a) filing
requirements applicable to Covered Persons were complied with through February
1996, except that the following reports were filed late: (1) the report of
changes of beneficial ownership on Form 4 for Edmund L. Zalinski, Ph.D, a
Director of the Company; and (2) the report of changes of beneficial ownership
on Form 5 for Frederick Cahn, Ph.D., the Company's Senior Vice President,
Technology. Dr. Zalinski's report on Form 4 involved a single transaction, and
Dr. Cahn's report on Form 5 involved two transactions.
4
<PAGE>
EXECUTIVE COMPENSATION
The following table sets forth certain information for the Company's last
three fiscal years concerning the annual, long-term and other compensation of
the chief executive officer of the Company and the other executive officers of
the Company whose total annual salary and bonus exceeded $100,000 during 1996
(collectively, the 'Named Officers'):
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM
COMPENSATION
ANNUAL AWARDS
COMPENSATION SECURITIES
------------------ UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY BONUS OPTIONS COMPENSATION(1)
- -------------------------------------------------- ---- -------- ------- ------------ ---------------
<S> <C> <C> <C> <C> <C>
Richard E. Caruso, Ph.D.(2) ...................... 1996 $165,000 -- -- $ 475
Chairman, President and 1995 $ 48,125 -- 170,000 --
Chief Executive Officer 1994 -- -- -- --
Michael D. Pierschbacher, Ph.D.(3) ............... 1996 $198,000 -- -- $ 1,485
Senior Vice President, Research 1995 $ 74,520 -- 170,000 --
and Development 1994 -- -- -- --
Andre P. Decarie ................................. 1996 $130,000 -- -- --
Senior Vice President, Marketing 1995 $130,200 -- -- --
and Sales 1994 $100,000 $20,000 -- --
John R. Emery(4) ................................. 1996 $130,000 -- -- --
Senior Vice President, Operations 1995 $103,096 -- -- --
and Finance 1994 $ 6,310 -- 170,000 --
Robert J. Towarnicki(5) .......................... 1996 $125,096 -- -- $ 925
Executive Vice President, Technology 1995 $136,033 -- -- $ 1,019
and Business Development 1994 $130,000 -- -- $ 120,559
Frederick Cahn, Ph.D. ............................ 1996 $115,000 -- 13,000 $ 858
Senior Vice President, Technology 1995 $ 97,492 -- -- $ 862
1994 $ 90,000 -- -- $ 506
</TABLE>
- ------------------
(1) Consists of the Company's matching contributions to the Company's 401(k)
Plan, except that the amount listed for Mr. Towarnicki for 1994 also
includes $120,000 as forgiveness of indebtedness to the Company.
(2) In September 1995, Dr. Caruso commenced receiving an annual salary of
$165,000.
(3) Dr. Pierschbacher's employment with the Company commenced in August 1995.
(4) Mr. Emery's employment with the Company commenced in December 1994. Mr.
Emery resigned as an officer of the Company in March 1997.
(5) Mr. Towarnicki resigned as a Director and an officer of the Company in
October 1996.
5
<PAGE>
The following tables set forth certain information concerning stock options
granted to the Named Officers during the fiscal year ended December 31, 1996 and
the unexercised options held by them at December 31, 1996:
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
--------------------------------------------------------
NUMBER OF % OF TOTAL
SECURITIES OPTIONS
UNDERLYING GRANTED TO EXERCISE
OPTIONS EMPLOYEES IN PRICE EXPIRATION
NAME GRANTED FISCAL YEAR (1) PER SHARE DATE
- -------------------------------------------------------------- ---------- --------------- --------- ----------
<S> <C> <C> <C> <C>
Richard E. Caruso, Ph.D....................................... -- -- -- --
Michael D. Pierschbacher, Ph.D................................ -- -- -- --
Andre P. Decarie.............................................. -- -- -- --
John R. Emery................................................. -- -- -- --
Robert J. Towarnicki.......................................... -- -- -- --
Frederick Cahn, Ph.D.......................................... 13,000(2) 6.2% $ 8.00 9/30/01
</TABLE>
- ------------------
(1) The Company granted options to employees to purchase a total of 209,250
shares of Common Stock during 1996.
(2) Such options were granted at a price above fair market value, are
nontransferable and vest at the rate of 2% per month commencing with the
date of grant.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND
FISCAL YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY
SHARES OPTIONS AT OPTIONS AT
ACQUIRED FISCAL YEAR END FISCAL YEAR END(2)
ON VALUE --------------------------- ---------------------------
NAME EXERCISE REALIZED(1) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ------------------------------------- ----------- ----------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Richard E. Caruso, Ph.D.............. -- -- 47,600 122,400 -- --
Michael D. Pierschbacher, Ph.D....... -- -- 54,400 115,600 -- --
Andre P. Decarie..................... 32,500 $ 175,900 113,700 23,800 -- --
John R. Emery........................ 25,000 $ 100,000 56,439 88,561 -- --
Robert J. Towarnicki................. 40,000 $ 297,800 257,500 -- $ 1,122,700 --
Frederick Cahn, Ph.D................. 16,975 $ 126,379 62,220 39,780 $ 51,121 $27,468
</TABLE>
- ------------------
(1) Calculated on the basis of the fair market value of the underlying
securities at the exercise date minus the exercise price.
(2) In-the-money options are those in which the fair market value of the
underlying securities exceeds the exercise price of the option. The closing
price of the Company's Common Stock on December 31, 1996 was $4.625 per
share.
EMPLOYMENT AGREEMENTS
Mr. Emery entered into a three-year employment agreement with the Company
on December 7, 1994 which provides for an initial annual base salary of $92,000,
with medical and health benefits. Pursuant to the agreement, the Company issued
to Mr. Emery options to purchase 170,000 shares of Common Stock at an exercise
price of $8.00 per share, subject to vesting through December 1999. By the terms
of the agreement, such options will expire three months after Mr. Emery is no
longer employed by the Company. Mr. Emery resigned as an officer of the Company
in March 1997.
6
<PAGE>
PRINCIPAL STOCKHOLDERS
The following table sets forth as of February 28, 1997 certain information
regarding the beneficial ownership of the Common Stock by: (a) each person or
entity known to the Company to own beneficially five percent or more of the
outstanding shares of Common Stock, based upon Company records or Securities and
Exchange Commission records; (b) each of the Company's directors; (c) each of
the Named Officers; and (d) all executive officers and directors of the Company
as a group. Except as otherwise indicated, each person has sole voting power and
sole investment power with respect to all shares beneficially owned by such
person.
<TABLE>
<CAPTION>
NUMBER OF
SHARES
BENEFICIALLY PERCENT OF
NAME OF BENEFICIAL OWNER OWNED(1) CLASS
- ------------------------------------------------------------------------------------ -------------- ----------
<S> <C> <C>
Richard E. Caruso, Ph.D. .......................................................... 14,457,811(2) 50.3%
105 Morgan Lane
Plainsboro, NJ 08536
Trust Partnership .................................................................. 14,358,411(3) 50.0
c/o Richard E. Caruso, Ph.D.
105 Morgan Lane
Plainsboro, NJ 08536
Frances C. Holtz ................................................................... 14,358,411(4) 50.0
8111 Marshall Avenue
Margate, NJ 08402
Union Carbide Corporation .......................................................... 3,150,561 11.0
39 Old Ridgebury Road
Danbury, CT 06817
State of Wisconsin Investment Board ................................................ 2,617,959 9.1
121 East Wilson Street
Madison, WI 53703
Robert J. Towarnicki................................................................ 224,420(5) *
Andre P. Decarie.................................................................... 120,500(6) *
Edmund L. Zalinski, Ph.D............................................................ 102,917(7) *
Frederick Cahn, Ph.D................................................................ 87,191(8) *
Michael D. Pierschbacher, Ph.D...................................................... 71,804(9) *
John R. Emery....................................................................... 63,521(10) *
William M. Goldstein, Esq........................................................... 31,541(6) *
Frederick V. Malek.................................................................. 29,417(6) *
George W. McKinney, III, Ph.D....................................................... 29,417(6) *
James M. Sullivan................................................................... 29,417(6) *
Keith Bradley, Ph.D................................................................. 7,117(6) *
All directors and executive officers
as a group (12 persons)........................................................... 15,175,653(11) 51.7%
</TABLE>
- ------------------
* Less than one percent (1%).
(1) Shares of Common Stock not outstanding but deemed beneficially owned by
virtue of the right of an individual to acquire them within 60 days upon the
exercise of an option are treated as outstanding for purposes of determining
beneficial ownership and the percentage beneficially owned by such
individual.
(2) Includes the 14,358,411 shares of Common Stock held by Trust Partnership, a
Pennsylvania general partnership of which Dr. Caruso is a partner and the
President (also see footnote 3 below). Also includes 43,200 shares of Common
Stock held by Provco Leasing Corporation ('Provco') of which Dr. Caruso is
President, and 1,800 shares of Common Stock issuable upon exercise of the
vested portion of options held by Provco. Provco is a wholly-owned
subsidiary of Cono Industries, a corporation whose stockholders are trusts
(Footnotes to table continued on next page)
7
<PAGE>
(Footnotes to table continued from previous page)
whose beneficiaries include Dr. Caruso's children. Also includes 54,400
shares of Common Stock issuable upon exercise of the vested portion of
options held by Dr. Caruso.
(3) The partners of Trust Partnership are Pagliacci Trust, Rigoletto Trust,
Trust for Jonathan Henry Caruso, Trust for Peter James Caruso (the
beneficiaries of all such trusts (the 'Trusts') being Dr. Caruso's
children), Dr. Caruso and Provco, each of which may be deemed to
beneficially own the shares of Common Stock held by Trust Partnership;
however, such partners of Trust Partnership disclaim beneficial ownership of
all such shares of Common Stock except to the extent represented by their
respective equity and profit participation interests in Trust Partnership.
(4) Frances C. Holtz is a trustee of the Trusts, which collectively have a
controlling interest in Trust Partnership. As such, Ms. Holtz may be deemed
to beneficially own the shares of Common Stock held by Trust Partnership;
however, Ms. Holtz disclaims beneficial ownership of all such shares of
Common Stock.
(5) Includes 181,520 shares of Common Stock issuable upon exercise of the vested
portion of outstanding options held by Mr. Towarnicki. Mr. Towarnicki
resigned as a Director and an officer of the Company in October 1996.
(6) Represents shares of Common Stock issuable upon exercise of the vested
portion of options.
(7) Includes 31,250 shares of Common Stock held by the Edmund L. Zalinski
Company and 18,070 shares of Common Stock held by Whitehall Court, L.P., a
family limited partnership whose beneficiaries include Dr. Zalinski's
children. Also includes 4,959 shares of Common Stock issuable upon exercise
of the vested portion of outstanding options held by Dr. Zalinski.
(8) Includes 67,140 shares of Common Stock issuable upon exercise of the vested
portion of outstanding options held by Dr. Cahn.
(9) Includes 8,856 shares of Common Stock held by a revocable trust of which Dr.
Pierschbacher is co-trustee. Also includes 61,200 shares of Common Stock
issuable upon exercise of the vested portion of outstanding options held by
Dr. Pierschbacher.
(10) Represents shares of Common Stock issuable upon exercise of the vested
portion of options. Mr. Emery resigned as an officer of the Company in
March 1997.
(11) See Notes 2 and 6 through 10 above. Also includes 145,000 shares of Common
Stock issuable upon exercise of the vested portion of options held by one
executive officer of the Company who is not listed in the table.
CERTAIN TRANSACTIONS
The Company leases its administrative, manufacturing, research and
principal warehouse facility in Plainsboro, New Jersey from Plainsboro
Associates, a New Jersey general partnership. Ocirne, Inc., a subsidiary of Cono
Industries, owns a 50% interest in Plainsboro Associates. Cono Industries is a
corporation whose stockholders are trusts whose beneficiaries include Dr.
Caruso's children. The Company paid approximately $185,000 in rent for this
facility during 1996.
Since 1993, the Company has received legal services from the law firm of
Drinker Biddle & Reath LLP, of which firm William M. Goldstein, a director of
the Company, is a partner.
The Company believes that each of the transactions described above was
entered into on an arm's-length basis in the ordinary course of the Company's
business.
STOCKHOLDER PROPOSALS
In order to be eligible for inclusion in the Company's proxy materials for
the 1998 Annual Meeting of Stockholders, stockholders' proposals to take action
at such meeting must comply with applicable Securities and Exchange Commission
rules and regulations, must be directed to the Secretary of the Company at its
offices set
8
<PAGE>
forth on page one of this Proxy Statement and must be received by the Company no
later than December 10, 1997.
OTHER MATTERS
A copy of the Company's 1996 Annual Report to Stockholders is being mailed
simultaneously herewith to stockholders but is not to be regarded as proxy
solicitation material.
THE COMPANY, UPON REQUEST, WILL FURNISH TO RECORD AND BENEFICIAL HOLDERS OF
ITS COMMON STOCK, FREE OF CHARGE, A COPY OF ITS ANNUAL REPORT ON FORM 10-K
(INCLUDING FINANCIAL STATEMENTS AND SCHEDULES BUT WITHOUT EXHIBITS) FOR THE
FISCAL YEAR ENDED DECEMBER 31, 1996. COPIES OF EXHIBITS TO THE FORM 10-K ALSO
WILL BE FURNISHED UPON REQUEST AND THE PAYMENT OF A REASONABLE FEE. ALL REQUESTS
SHOULD BE DIRECTED TO JUDY BRENNA, INVESTOR RELATIONS, AT THE OFFICES OF THE
COMPANY SET FORTH ON PAGE ONE OF THIS PROXY STATEMENT.
By order of the Board of Directors,
/s/ William M. Goldstein
William M. Goldstein
April 16, 1997 Secretary
9
<PAGE>
INTEGRA LIFESCIENCES CORPORATION
105 MORGAN LANE
PLAINSBORO, NEW JERSEY 08536
PROXY--Annual Meeting of Stockholders--Monday, May 19, 1997
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned hereby appoints Richard E. Caruso, Ph.D., and William M.
Goldstein, Esq., as proxies, each with the power to appoint his substitute, and
hereby authorizes them to represent and to vote, as designated on the reverse,
all the shares of Common Stock of Integra LifeSciences Corporation held of
record by the undersigned on March 31, 1997 at the Annual Meeting of
Stockholders to be held on Monday, May 19, 1997 or at any adjournment or
postponement thereof.
(Continued, and to be signed, on Reverse Side)
<PAGE>
Please mark /x/
your votes as
indicated in
this example
WITHHOLD
FOR ALL NOMINEES LISTED AUTHORITY
(EXCEPT AS MARKED TO TO VOTE FOR ALL NOMINEES
THE CONTRARY BELOW) LISTED AT RIGHT
1. ELECTION OF DIRECTORS. / / / /
NOMINEES:
Keith Bradley, Ph.D.
Richard E. Caruso, Ph.D.
William M. Goldstein, Esq.
Frederic V. Malek
George W. McKinney, III, Ph.D.
James M. Sullivan
Edmund L. Zalinski, Ph.D.
(INSTRUCTIONS: To withhold authority to vote for
any individual nominee, write that nominee's name below.)
- -----------------------------------------
2. Proposal to ratify the appointment of Coopers & Lybrand L.L.P. as the
independent accountants of the Company for the year ending December 31,
1997.
FOR AGAINST ABSTAIN
/ / / / / /
3. In their discretion, the Proxies are authorized, to the extent permitted by
the rules of the Securities and Exchange Commission, to vote upon such other
business as may properly come before the meeting or any adjournment or
postponement thereof.
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE MANNER DIRECTED
HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL
BE VOTED IN FAVOR OF ALL NOMINEES LISTED FOR ELECTION AS DIRECTORS; FOR PROPOSAL
2; AND IN ACCORDANCE WITH THE PROXIES' JUDGMENT UPON OTHER MATTERS PROPERLY
COMING BEFORE THE MEETING AND ANY ADJOURNMENTS THEREOF.
PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED
ENVELOPE.
SIGNATURE ________ DATE ________________ SIGNATURE _______ DATE ________________
NOTE: Please sign exactly as name appears above. When shares are held by joint
tenants, both should sign. When signing as attorney, executor, administrator,
trustee or guardian, please give full title as such. If a corporation, please
sign with full corporate name by President or other authorized officer. If a
partnership, please sign in partnership name by authorized person.
FOLD AND DETACH HERE
